非小细胞肺癌KRASG12C突变的研究进展

doi:10.3760/cma.j.cn371439-20231008-00013

摘要/Abstract

摘要：

随着KRAS^G12C突变在非小细胞肺癌靶向治疗中作用机制的不断深入研究，KRAS^G12C由“不可成药”发展为重要的靶向治疗位点。KRAS^G12C突变抑制剂在非小细胞肺癌靶向治疗中实现了有效率和生存的双进展。尽管治疗产生的耐药不可避免，但通过其耐药机制的研究发现，联合用药是克服或减少耐药的途径之一。

关键词: KRAS, 癌, 非小细胞肺, 分子靶向治疗

Abstract:

With the continuous in-depth research on the mechanism of KRAS^G12Cmutations in targeted therapy of non-small cell lung cancer，KRAS^G12C has evolved from non producible to an important targeted therapy site. The KRAS^G12C mutation inhibitor has achieved dual progress in efficiency and survival in targeted therapy of non-small cell lung cancer. Although drug resistance is inevitable with treatment，research on drug resistance mechanisms has found that combination medication is one of the ways to overcome or reduce drug resistance.

Key words: KRAS, Carcinoma, non-small-cell lung, Molecular targeted therapies

马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.

Ma Zhenghong, Jiang Chao. Progress of KRAS^G12C mutations in non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 95-98.

参考文献 38

[1]	Liu P, Wang Y, Xin L. Targeting the untargetable KRAS in cancer therapy[J]. Acta Pharm Sin B, 2019, 9(5): 871-879. DOI: 10.1016/j.apsb.2019.03.002. pmid: 31649840
[2]	Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer[J]. Cancer Metastasis Rev, 2020, 39(4): 1029-1038. DOI: 10.1007/s10555-020-09915-5.
[3]	Judd J, Abdel Karim N, Khan H, et al. Characterization of KRAS mutation subtypes in non-small cell lung cancer[J]. Mol Cancer Ther, 2021, 20(12): 2577-2584. DOI: 10.1158/1535-7163.MCT-21-0201. pmid: 34518295
[4]	Ricciuti B, Alessi JV, Elkrief A, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS^G12D-mutated non-small-cell lung cancer[J]. Ann Oncol, 2022, 33(10): 1029-1040. DOI: 10.1016/j.annonc.2022.07.005. pmid: 35872166
[5]	Negrao MV, Araujo HA, Lamberti G, et al. Comutations and KRAS^G12C inhibitor efficacy in advanced NSCLC[J]. Cancer Discov, 2023, 13(7): 1556-1571. DOI: 10.1158/2159-8290.CD-22-1420.
[6]	Sebastian M, Eberhardt WEE, Hoffknecht P, et al. KRAS^G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)[J]. Lung Cancer, 2021, 154: 51-61. DOI: 10.1016/j.lungcan.2021.02.005. pmid: 33611226
[7]	Cui W, Franchini F, Alexander M, et al. Real world outcomes in KRAS^G12C mutation positive non-small cell lung cancer[J]. Lung Cancer, 2020, 146: 310-317. DOI: 10.1016/j.lungcan.2020.06.030.
[8]	Wu MY, Zhang EW, Strickland MR, et al. Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation[J]. Cancers (Basel), 2021, 13(14): 3572. DOI: 10.3390/cancers13143572.
[9]	Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches[J]. Ann Oncol, 2021, 32(9): 1101-1110. DOI: 10.1016/j.annonc.2021.06.001. pmid: 34089836
[10]	Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS^G12C somatic mutations across race, sex, and cancer type[J]. N Engl J Med, 2021, 384(2): 185-187. DOI: 10.1056/NEJMc2030638.
[11]	Ou SI, Jänne PA, Leal TA, et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS^G12C solid tumors (KRYSTAL-1)[J]. J Clin Oncol, 2022, 40(23): 2530-2538. DOI: 10.1200/JCO.21.02752.
[12]	Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2021, 27(8): 2209-2215. DOI: 10.1158/1078-0432.CCR-20-4023. pmid: 33558425
[13]	Hong DS, Fakih MG, Strickler JH, et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217. DOI: 10.1056/NEJMoa1917239.
[14]	Ferdinandos S, Bob TL, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation[J]. N Engl J Med, 2021, 384(25): 2371-2381. DOI: 10.1056/NEJMoa2103695.
[15]	Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition[J]. Nature, 2020, 577(7790): 421-425. DOI: 10.1038/s41586-019-1884-x.
[16]	Koster KL, Appenzeller C, Lauber A, et al. Sotorasib shows intracranial activity in patients with KRAS^G12C-mutated adenocarcinoma of the lung and untreated active brain metastases[J]. Case Rep Oncol, 2022, 15(2): 720-725. DOI: 10.1159/000525341.
[17]	Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions[J]. Nature, 2013, 503(7477): 548-551. DOI: 10.1038/nature12796.
[18]	O'Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors[J]. Pharmacol Res, 2019, 139: 503-511. DOI: 10.1016/j.phrs.2018.10.021. pmid: 30366101
[19]	Hallin J, Engstrom LD, Hargis L, et al. The KRAS^G12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10(1): 54-71. DOI: 10.1158/2159-8290.CD-19-1167. pmid: 31658955
[20]	Grace KD, Ramaswamy G, Vamsidhar V, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100[J]. J Clin Oncol, 2023, 41(18): 3311-3317. DOI: 10.1200/JCO.22.02524.
[21]	Brazel D, Kim J, Ou SI. CodeBreaK 200: sotorasib (AMG510) has broken the KRAS G12C⁺ NSCLC enigma code[J]. Lung Cancer (Auckl), 2023, 14: 31-39. DOI: 10.2147/LCTT.S403614.
[22]	Isaksson J, Berglund A, Louie K, et al. KRAS^G12C mutant non-small cell lung cancer linked to female sex and high risk of CNS metastasis: population-based demographics and survival data from the National Swedish Lung Cancer Registry[J]. Clin Lung Cancer, 2023, 24(6): 507-518. DOI: 10.1016/j.cllc.2023.05.002. pmid: 37296038
[23]	Sabari JK, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRAS^G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2022, 28(15): 3318-3328. DOI: 10.1158/1078-0432.CCR-22-0383. pmid: 35404402
[24]	Negrao MV, Spira AI, Heist RS, et al. Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRAS^G12C-mutated non-small-cell lung cancer who have untreated CNS metastases[J]. J Clin Oncol, 2023, 41(28): 4472-4477. DOI: 10.1200/JCO.23.00046.
[25]	Zhang J, Johnson M, Barve M, et al. Practical guidance for the management of adverse events in patients with KRAS^G12C-mutated non-small cell lung cancer receiving adagrasib[J]. Oncologist, 2023, 28(4): 287-296. DOI: 10.1093/oncolo/oyad051. pmid: 36892150
[26]	Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRAS^G12C mutation[J]. J Clin Oncol, 2023, 41(25): 4097-4106. DOI: 10.1200/JCO.23.00434.
[27]	Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition[J]. Nature, 2021, 599(7886): 679-683. DOI: 10.1038/s41586-021-04065-2.
[28]	Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781): 217-223. DOI: 10.1038/s41586-019-1694-1.
[29]	Pantsar T. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations[J]. Sci Rep, 2020, 10(1): 11992. DOI: 10.1038/s41598-020-68950-y.
[30]	Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS^G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments[J]. J Thorac Oncol, 2021, 16(8): 1321-1332. DOI: 10.1016/j.jtho.2021.04.015.
[31]	Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival[J]. Cancer Cell, 2021, 39(3): 441-442. DOI: 10.1016/j.ccell.2021.02.009.
[32]	Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS^G12C inhibition in cancer[J]. N Engl J Med, 2021, 384(25): 2382-2393. DOI: 10.1056/NEJMoa2105281.
[33]	Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS^G12C inhibition in colorectal cancer[J]. Cancer Discov, 2020, 10(8): 1129-1139. DOI: 10.1158/2159-8290.CD-20-0187. pmid: 32430388
[34]	Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRAS^G12C-EGFR inhibition in colorectal cancer[J]. Cancer Discov, 2023, 13(1): 41-55. DOI: 10.1158/2159-8290.CD-22-0405.
[35]	Zhang SS, Nagasaka M. Spotlight on sotorasib (AMG 510) for KRAS^G12C positive non-small cell lung cancer[J]. Lung Cancer (Auckl), 2021, 12: 115-122. DOI: 10.2147/LCTT.S334623.
[36]	Christofyllakis K, Monteiro AR, Cetin O, et al. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: a young International Society of Geriatric Oncology report[J]. J Geriatr Oncol, 2022, 13(8): 1071-1083. DOI: 10.1016/j.jgo.2022.04.013. pmid: 35525790
[37]	Brown WS, McDonald PC, Nemirovsky O, et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer[J]. Cell Rep Med, 2020, 1(8): 100131. DOI: 10.1016/j.xcrm.2020.100131.
[38]	Hamarsheh S, Groß O, Brummer T, et al. Immune modulatory effects of oncogenic KRAS in cancer[J]. Nat Commun, 2020, 11(1): 5439. DOI: 10.1038/s41467-020-19288-6. pmid: 33116132